ceritinib
The researchers combined different proteomic methods to explore the activity of the ALK inhibitor ceritinib and identify potential combination therapies.
Roche ALK Test Gains FDA Approval as CDx for Zykadia
The IHC test was used in clinical studies that led to Zykadia's approval last week as a first-line option for metastatic NSCLC patients with ALK rearrangements.
Novartis' Zykadia Approved for Frontline Treatment of Metastatic, ALK-Positive NSCLC
The expanded indication makes it a first-line option for metastatic non-small cell lung cancer patients with ALK rearrangements.
EU's CHMP Grants Conditional Marketing Authorization to Novartis' Personalized NSCLC Rx Zykadia
Premium
Zykadia received conditional marketing authorization as a treatment for advanced NSCLC patients who've previously received the ALK inhibitor Xalkori, and so are known to be ALK positive.